Holen Sie sich die Stockscreener-App
39.73
0.89%
0.35
Schlusskurs vom Vortag:
$39.38
Offen:
$39.96
24-Stunden-Volumen:
230.32K
Relative Volume:
0.59
Marktkapitalisierung:
$3.03B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-14.50
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
+2.11%
1M Leistung:
+1.92%
6M Leistung:
+1.51%
1J Leistung:
-18.64%
1-Tages-Spanne:
$39.32
$40.00
1-Wochen-Bereich:
$37.68
$40.00
52-Wochen-Spanne:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.73 | 3.03B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - Defense World
TimesSquare Capital Management LLC Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon Pharmaceuticals to Announce Q4 and Full Year 2024 Financial Results - TipRanks
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Can Xenon's Promising Epilepsy Drug Pipeline Deliver? Q4 Results Will Tell - StockTitan
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight - GlobeNewswire Inc.
(XENE) Trading Advice - Stock Traders Daily
Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Armenian Reporter
Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Defense World
Deutsche Bank Aktiengesellschaft Begins Coverage on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $56.00 - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Deutsche Bank Aktiengesellschaft - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.00 Average Target Price from Analysts - Defense World
abrdn plc Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Deutsche Bank Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - Nasdaq
XENE stock rated an Outperform by Raymond James - Knox Daily
Deutsche Bank Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $67 Price Target - Marketscreener.com
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Jennison Associates LLC - MarketBeat
Blue Trust Inc. Raises Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
FY2025 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst - MarketBeat
SG Americas Securities LLC Buys 5,577 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings - Defense World
Learn to Evaluate (XENE) using the Charts - Stock Traders Daily
2,569 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Avior Wealth Management LLC - Defense World
Ian Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock - MarketBeat
Wedbush Lowers Earnings Estimates for Xenon Pharmaceuticals - Defense World
Q1 EPS Estimates for Xenon Pharmaceuticals Cut by Wedbush - MarketBeat
FY2029 Earnings Forecast for XENE Issued By Wedbush - Defense World
Cantor Fitzgerald Predicts XENE FY2025 Earnings - Defense World
Cantor Fitzgerald Estimates XENE FY2025 Earnings - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Epidemic Keratoconjunctivitis Market Expected to Reach Huge - openPR
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals announces executive changes By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):